Searched for
NEUROLOGY PORTFOLIO
Should they now be part of a long-term investing framework? 7 healthcare stocks with upside potential of up to 25%India’s healthcare market may grow steadily, but hospital chains can grow faster as formalisation continues. Healthcare is all about market...- These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...
- For investors who focus on the long term: 5 mid-cap stocks from different sectors with upside potential up to 28%When prices fall, caution comes naturally. Investors hesitate, portfolios are reviewed less often, and even optimists become careful. But w...
- Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...
- These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 26%On Thursday evening, US President Trump said he would “hit Iran hard tonight”. Then, as the world waited with bated breath, came the announ...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- For risk-takers with long-term perspective: 10 small-cap stocks from different sectors with upside potential of up to 31%If you buy small-cap stocks today, are you taking a risk or managing it? To some it might appear you are taking a risk, but there is a high...
- Open to 4-5 acquisitions, but at sensible valuations: Ameera Shah, promoter and executive chairperson, Metropolis HealthcareMetropolis Healthcare is set for its next growth phase. The diagnostic chain will focus on genomics and specialty diagnostics. Strategic ac...
- Wealth creation is also about ignoring noise on the street: 15 mid- and small-cap stocks from different sectors which fit the billIn the April 2022-September 2024 bull market, every management appeared capable. Margins expanded, working capital looked manageable, capit...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%We are living in times when the morning may see conciliatory exchanges between the US and Iran, leading to a cooling in crude oil prices. B...
- War, oil price hikes, and risks: Time to still be contrarian? 5 small-caps from different sectors with upside potential of up to 25%Small-cap investing is not just about finding stocks that can rise faster than the market, which is the assumption with which most investor...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%It is not every day that you see crude oil prices moving higher and the Asian markets, including India, also inching higher. Now, as an inv...
- Roche Pharma launches multiple sclerosis treatment drug in IndiaThe company has introduced Ocrevus (Ocrelizumab) which is the first and only approved disease modifying therapy for both Relapsing Remittin...
- Eris Lifesciences scouting for acquisitions to diversify bizThrough acquisition of Strides domestic formulations portfolio in 2017, Eris Lifesciences got a toehold in the neurology and psychiatry seg...
- Dr Reddy’s Q2 numbers in line with estimatesDr Reddy’s has come out with a decent set of numbers on revenue, EBITDA and profitability fronts, says Nikhil Shetty.
- Dr Reddy's Laboratories may file new drug applications with FDA within yearChief Operating Officer and Member of the Management Council, DRL, Abhijit Mukherjee said one drug is currently in the late phase-III .
Load More
